Mankind Pharma Ltd

Stage 2 · Advancing · week 2Setup 8.5 ★★★ PrimeStrong +0.7

As of 20 Nov 2026, Mankind Pharma is in Stage 2, the uptrend phase, now in week 2 (since 13 Nov 2026). It closed at ₹2,665, at its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. More about the company

₹2,665
Close, 20 Nov 2026
+1.37% on the day
₹1.10L Cr · Large cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Early entry: still early enough in its move

Setup score

8.5 ★★★ Prime

RS rank

Edge

Strong +0.7

MANKIND is 2 weeks into its Stage 2 advance, 9% above its 50-day average and at its 52-week high. The first weeks are when a move is least proven; a close back below its 50-day average would be the first sign of trouble.

Its relative strength is 78 of 99, above the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Stocks with a similar setup at this point in their move ran 0.7 points ahead of the average stock over the next 30 sessions on average, after costs, and their typical best close within 60 sessions was 16% above entry.

The trend read holds while it stays in Stage 2. A close below ₹2,443, its 50-day average, would put it at rest; ₹2,135, 20% under its 52-week high of ₹2,668, is where a trailing stop would sit.

Setup-score rank among Stage 2 peers: #16 of 50 in Pharmaceuticals · #21 of 61 in Health Care

Is MANKIND early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S? 26w
S2 15w
S2 23w
S4 23w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 26w → S2 15w → S3 10w → S2 23w → S3 6w → S4 8w → S1 7w → S4 4w → S1 5w → S2 5w → S3 6w → S4 23w → S1 6w → S2 13w → S3 9w → S2 1w current
Total tracked: 168 weeks across 16 stage runs.

MANKIND among Pharmaceuticals49th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…49MANKINDStage 2 · wk 278+16.6%
vs 52W High
-0.1%
₹1,927.4 lo₹2,668.3 hi
Near 52W high
How far this stock is from its 52-week high. A stock a little below its high with its Stage 2 structure intact is in a pullback, not a breakdown.
Stage Maturity
Week 2
1w13w26w
Week 2, fresh breakout
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
13.7%
200 DMA: ₹2,343.3 · rising
The stock is above its 200-day average, the long-term trend line. That is where a Stage 2 advance normally trades.
Rel Volume
0.72x
vs 50-day avg
Volume was close to average, nothing unusual. In a Stage 2 advance, look for heavy volume on breakouts and quiet volume on pullbacks.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+16.6%
3M
+11.3%
6M
+3.1%
YTD
+21.3%
1Y
+18.1%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
This stock ranks #41 of 58 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Ranks #34 of 48 Stage 2 stocks in this industry.

Mutual fund holdings

Held by 142 mutual funds in portfolios to October 2026: 84 active funds and 58 index funds and ETFs.

In October, among active funds: 18 increased, 12 opened a new position, 9 reduced and 5 exited.

30 increased or opened14 reduced or exited
Largest active holders, by weight in the fund
All 142 funds, the 5 that exited, and what each did in October

Mutual funds holding MANKIND: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
In the scan on 13 Nov 2026
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-11-20S2
Wk 2 · Vol 0.72x
2026-11-19S2
Wk 1 · Vol 0.33x
2026-11-18S2
Wk 1 · Vol 0.54x
2026-11-17S2
Wk 1 · Vol 0.52x
2026-11-16S2
Wk 1 · Vol 0.68x
2026-11-13S23→2
Wk 1 · Vol 0.79x
2026-11-12S3
Wk 9 · Vol 0.68x
2026-11-11S3
Wk 9 · Vol 1.38x
2026-11-09S3
Wk 9 · Vol 2.57x
2026-11-06S3
Wk 8 · Vol 0.46x
2026-11-05S3
Wk 8 · Vol 0.64x
2026-11-04S3
Wk 8 · Vol 1.13x
Moving averages & range
50 DMA
₹2,443.1
200 DMA
₹2,343.3
52W High
₹2,668.3
52W Low
₹1,927.4
5D Low
₹2,610
Resistance levels (recent highs)
20d High
₹2,668.3
60d High
₹2,668.3
120d High
₹2,668.3
250d High
₹2,668.3
Next resistance
+0.1%
to 20d High
P/E (TTM)
49.1
Forward 37.1
Earnings Growth (YoY)
+38.9%
Revenue +17.3%
ROE
+13.6%
Profit margin +14.6%
Dividend Yield
0.00%
P/B 6.3

Mankind Pharma: quick answers

What stage is Mankind Pharma in?

As of 20 Nov 2026, Mankind Pharma (MANKIND) is in Stage 2, the uptrend phase. It entered Stage 2 on 13 Nov 2026 and is in week 2. What the four stages mean

Is Mankind Pharma in an uptrend?

Yes. Mankind Pharma is in a Stage 2 uptrend. It trades 13.7% above its 200-day average, which is rising.

How far is Mankind Pharma from its 52-week high?

Mankind Pharma closed at ₹2,665 on 20 Nov 2026, at its 52-week high. Its 52-week low is ₹1,927.

How has Mankind Pharma performed over the past year?

As of 20 Nov 2026, Mankind Pharma is up 18.1% over the past year and up 21.3% so far in 2026.

Is Mankind Pharma in F&O, and what is its lot size?

Yes. Mankind Pharma (MANKIND) trades in NSE's F&O segment, with a near-month lot size of 250 shares as of 20 Nov 2026. NSE revises lot sizes a few times a year; ours are reloaded from the exchange's list after every close.

Which sector and industry is Mankind Pharma in?

Mankind Pharma is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.